dm+d

Unassigned

New Medicines

Information

New molecular entity
Janssen
Johnson & Johnson

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Aug 20Development discontinued after negative interim analysis from PIII RCT (NCT03376321) [8].

Category

First-in-class non-nucleotide inhibitor of the PB2 subunit of the influenza A polymerase complex. Oral dose expected to be 600mg twice daily.
Up to 15% of the population can develop influenza in any year. There is a 10-20% seroconversion rate with or without symptoms. In an average year, there are 50-200 GP consultations for influenza or flu-like illnesses per 100,000 population per week [1].
Acute influenza A in patients aged 13 years and older at risk of influenza-related complications, including hospitalized patients - in conjunction with standard of care
Intravenous and
Oral